Zevra Therapeutics (NASDAQ:ZVRA) Issues Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) issued its quarterly earnings results on Tuesday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28), Zacks reports. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Zevra Therapeutics Trading Down 1.9 %

Shares of NASDAQ ZVRA opened at $7.92 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a market cap of $422.74 million, a price-to-earnings ratio of -4.02 and a beta of 1.98. The business has a fifty day simple moving average of $7.95 and a 200-day simple moving average of $8.14.

Insider Buying and Selling

In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at $231,759.96. The trade was a 26.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ZVRA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Guggenheim set a $21.00 target price on shares of Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday. Finally, Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $21.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.